Medicenna Therapeutics Corp is having a tough trading day, with shares down 2.70% despite no significant news.
In the latest trading session, Medicenna Therapeutics Corp (MDNA.TO) saw its stock price drop by 2.70%, closing at CA$0.36. This decline comes without any major updates to explain the downturn, leaving investors wondering about the reasons behind the weakness.
Investor takeaway: Investors should stay cautious as Medicenna's stock continues to face pressure, which may reflect broader market sentiment or specific challenges within the company.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.23M
52W high
$1.97
52W low
$0.34
1W change
+2.86%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 788.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+788.9% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
34.7%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.30
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.38 |
| 60 trading days | C$0.32 | C$0.27 – C$0.38 |
| 90 trading days | C$0.30 | C$0.24 – C$0.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medicenna's Market Cap Falls Below CA$35 Million
With a market cap of CA$34.15 million, Medicenna is under significant financial scrutiny, raising concerns about its future viability.
Bull case
If Medicenna can successfully navigate its public offering and use the funds raised for clinical advancements, there could be a turnaround in investor confidence.
Bear case
Ongoing declines might indicate deeper issues within the company, especially if they struggle to meet Nasdaq compliance or fail to achieve clinical milestones.
Market Reaction
Advertisement
The recent drop in Medicenna's stock price shows investor uncertainty. The lack of significant news or updates from the company may have added to the bearish sentiment, as shareholders seek reassurances about the company's financial health and strategic direction.
Future Outlook
Looking ahead, Medicenna's ability to stabilize its stock price will depend on its upcoming public offering and progress in its clinical programs. Investors will be closely watching these developments as they evaluate the company's potential for recovery.
Investor Sentiment
With a current market cap of CA$34.15 million, the pressure on Medicenna's stock raises questions about its long-term sustainability. Investors should keep an eye on upcoming announcements and market conditions that could affect the company's future.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
